MedTrace Logo

A Study of Duloxetine in Fibromyalgia

NCT01552057 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 393

Last updated 2015-01-16

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to assess the effectiveness and safety of duloxetine in participants with fibromyalgia.

Conditions

  • Fibromyalgia

Interventions

DRUG

Duloxetine 60 mg

Duloxetine 60 mg taken orally once every day for 15 weeks

DRUG

Placebo

Placebo taken orally once every day for 15 weeks

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01552057 on ClinicalTrials.gov